SynthesisBMC endocrine disorders2022
The effect of medication on serum anti-müllerian hormone (AMH) levels in women of reproductive age: a meta-analysis.
Synthesis in BMC endocrine disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Effect of metformin on anti-mullerian hormone levels in women with polycystic ovarian syndrome: a systematic review and meta-regression analysis of randomized controlled trials with.BMC endocrine disorders · 2024Pooled it
- The effects of metformin on anti-Müllerian hormone levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis.Journal of ovarian research · 2023Pooled it
- Incident endometriosis diagnosis and AMH: how surgical staging and typology relate to serum AMH levels.American journal of obstetrics and gynecology · 2026Article
- Recurrent Giant Ovarian Cysts in Biological Sisters: 2 Case Reports and Literature Review-Giant Ovarian Cysts in 2 Sisters.Healthcare (Basel, Switzerland) · 2025Article
- How to Preserve Fertility in Reproductive-Age Women with Cancer.Journal of clinical medicine · 2025Review
- Modulatory impact ofmSphere · 2025Article
- OvaRePred (HerTempo): an enhanced ovarian aging clock for personalized reserve assessment, endocrine age modeling, and predicting reproductive milestones across the female lifecycle.Frontiers in endocrinology · 2025Article
- Association between anti-mullerian hormone and metabolic syndrome: insights from a prospective community-based study.BMC endocrine disorders · 2024Article
- The Associations of Vitamin D with Ovarian Reserve Markers and Depression: A Narrative Literature Review.Nutrients · 2023Review
- Investigation of the Prevalence of Diminished Ovarian Reserve in Korean Women of Reproductive Age.Journal of clinical medicine · 2023Article
- Antimüllerian Hormone as a Tool to Predict the Age at Menopause.Geriatrics (Basel, Switzerland) · 2023Article
- Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Review
- The Role of Serum Anti-Mullerian Hormone Measurement in the Diagnosis of Polycystic Ovary Syndrome.Diagnostics (Basel, Switzerland) · 2023Review
- Women's health, hormonal balance, and personal autonomy.Frontiers in medicine · 2023Review
- Endocrine roles of vitamin D in female reproduction: Mechanisms and clinical implications.Women's health (London, England)Review
- Anti-Mullerian Hormone and Fertility Treatment Decisions in Polycystic Ovary Syndrome: A Literature Review.Journal of human reproductive sciencesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe study aims to address whether serum anti-müllerian hormone (AMH) levels fluctuate in the short term after medication application, including oral contraceptives (OCs), metformin (MET), Gonadotropin-releasing hormone agonist (GnRH-a), dehydroepiandrosterone (DHEA), vitamin D (VD), clomiphene citrate (CC), and letrozole (LET).
methodsPublished literature from PubMed, Embase, and Cochrane central was retrieved up until 19 September 2021. A total of 51 self-control studies with an average Newcastle-Ottawa quality assessment scale (NOS) score of 6.90 were analyzed. The extracted data were entered into Stata software, and the weighted mean difference/standardized mean difference (WMD/SMD) and 95% confidence interval (CI) were used for data analysis.
resultsAfter OCs treatment the AMH level showed a significant decline in women with normal ovarian function, which was significant within 3 months (WMD = -1.43, 95% CI: -2.05 to -0.80, P < 0.00001). After MET treatment, the serum AMH decreased in polycystic ovary syndrome (PCOS) patients (WMD = -1.79, 95% CI: -2.32 to -1.26, P < 0.00001), in both obese and non-obese patients. GnRH-a treatment in endometriosis patients led to dynamic changes in the serum AMH levels, that is, ascent at 1 month (P = 0.05), and descent at 3 months (P = 0.02). After DHEA treatment the serum AMH increased in diminished ovarian reserve (DOR) / poor ovarian response (POR) patients (WMD = 0.18, 95% CI: 0.09 to 0.27, P < 0.0001). After VD treatment the serum AMH increased, and it was obvious in non-PCOS patients (WMD = 0.78, 95% CI: 0.34 to 1.21, P = 0.0004). After CC treatment the serum AMH decreased significantly in PCOS patients, specifically in non-obese patients (WMD = -1.24, 95% CI: -1.87 to -0.61, P = 0.0001).
conclusionsSerum AMH levels may be affected in the short term after drug application. Specifically, OC, MET and CC lead to decreased AMH level, DHEA and VD lead to increased AMH level, and GnRH-a leads to dynamic variation, which is correlated with PCOS, obesity, age, and duration of medication. The impacts of these medications should be taken into consideration when AMH is used as a marker of ovarian reserve.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.